ARA-290

ARA-290, also known as cibinetide, is an 11-amino-acid synthetic peptide engineered from the helix-B domain of erythropoietin (EPO). It was developed to selectively engage tissue-protective signaling pathways while avoiding the hematopoietic activity associated with native EPO. In laboratory settings, ARA-290 serves as a tool compound for examining non-erythropoietic EPO-derived effects in controlled experimental systems. Research-use preparations are supplied strictly for in-vitro and laboratory investigation.

ARA-290 is studied for its interaction with the innate repair receptor, a heteromeric complex formed by the EPO receptor and the beta-common receptor (CD131). Binding is examined for downstream modulation of anti-inflammatory and cytoprotective signaling cascades without activation of pathways that drive red-blood-cell production. Investigators use the peptide to probe how selective receptor engagement influences cellular stress responses and inflammatory mediator profiles in model systems. This separation of activities allows isolation of tissue-protective mechanisms from erythropoietic confounders.

Laboratory research on ARA-290 centers on neuropathic, inflammatory, and metabolic-stress model systems in which erythropoietic stimulation would interfere with experimental endpoints. Studies commonly employ cultured cells, tissue explants, and defined in-vitro assays to map innate-repair-receptor-dependent signaling. The compound is also used to investigate resolution of inflammatory cascades and cellular resilience under oxidative or metabolic challenge. These applications remain confined to controlled research environments.

Published experimental work indicates that ARA-290 can activate the innate repair receptor complex and influence secondary messenger pathways linked to reduced pro-inflammatory cytokine output in cell-based assays. Investigations have documented selective engagement of cytoprotective gene programs without measurable stimulation of erythroid progenitor proliferation under standard laboratory conditions. Findings consistently highlight the utility of the peptide for dissecting EPO-related tissue-protection pathways independent of hematopoiesis. All observations derive from non-clinical model systems.

ARA-290 is supplied exclusively for in-vitro and laboratory research use and is not intended for any form of administration. Standard peptide-handling practices apply, including storage under recommended temperature and protection from repeated freeze-thaw cycles to preserve structural integrity. Researchers should confirm peptide identity and purity by appropriate analytical methods before incorporation into experimental designs. All work must remain within institutional biosafety and research-use guidelines.